Actemra (active ingredient tocilizumab) 400 mg/20 mL is a prescription biologic medication used to treat several serious inflammatory and autoimmune conditions. It is a monoclonal antibody that works by blocking the interleukin-6 (IL-6) receptor, a protein in the body that triggers inflammation.
Common Uses
Actemra is primarily prescribed for:
Rheumatoid Arthritis (RA): Moderate to severe active RA in adults.
Juvenile Idiopathic Arthritis: Both systemic (sJIA) and polyarticular (pJIA) forms in children aged 2 and older.
Giant Cell Arteritis: A condition causing inflammation of the blood vessels.
Cytokine Release Syndrome (CRS): Severe reactions caused by certain cancer treatments like CAR T-cell therapy.
COVID-19: Treatment for hospitalised adults receiving corticosteroids who require supplemental oxygen.
Product Details
Form: A concentrated solution for intravenous (IV) infusion.
Strength: 400 mg of tocilizumab in a 20 mL single-dose vial (20 mg/mL).
Administration: It must be diluted by a healthcare professional and given as a 60-minute drip infusion.
Manufacturer: Primarily produced by Roche (and its subsidiary Genentech).
Safety and Side Effects
Because it suppresses the immune system, Actemra can increase the risk of serious infections. Common side effects include:
Upper respiratory tract infections (coughs, sore throats).
Headaches and dizziness.
High blood pressure and increased cholesterol levels.
Reviews
There are no reviews yet.